AR027033A1 - Composicion estable para dosis oral de liberacion extendida - Google Patents

Composicion estable para dosis oral de liberacion extendida

Info

Publication number
AR027033A1
AR027033A1 ARP000106790A ARP000106790A AR027033A1 AR 027033 A1 AR027033 A1 AR 027033A1 AR P000106790 A ARP000106790 A AR P000106790A AR P000106790 A ARP000106790 A AR P000106790A AR 027033 A1 AR027033 A1 AR 027033A1
Authority
AR
Argentina
Prior art keywords
hours
extended release
pseudoephedrine
stable composition
composition
Prior art date
Application number
ARP000106790A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22629437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR027033(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR027033A1 publication Critical patent/AR027033A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toys (AREA)
  • Cosmetics (AREA)

Abstract

Se describe una composicion para dosis oral solida de liberacion extendida revestida con una película que contiene un descongestivo nasal, pseudoefedrinao su sal, por ejemplo, sulfato de pseudoefredina en un nucleo efectivo como para proporcionar una concentracion en plasma máxima geométrica de pseudoefredrinaentre alrededor de 345ng/ml y alrededor de 365 ng/ml en un tiempo entre alrededor de 7,60 horas y alrededor de 8,40 horas y que tiene dos o tres revestimientosde película sobre el nucleo, e l segundo contiene una cantidad de antihistamina, no sedativa desloratadina, efectiva como para proporcionar una concentracion enplasma máximo geométrica de desloratadina entre alrededor de 2,15 ng/ml y alrededor de 2,45 ng/ml en un tiempo entre alre dedor de 4,0 horas y alrededor de 4,5horas, y el uso de la composicion para tratar pacientes que muestran signos y síntomas asociados con las condiciones alérgicas y/o inflamatorias de la piel yde las vías aéreas.
ARP000106790A 1999-12-20 2000-12-20 Composicion estable para dosis oral de liberacion extendida AR027033A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17283699P 1999-12-20 1999-12-20

Publications (1)

Publication Number Publication Date
AR027033A1 true AR027033A1 (es) 2003-03-12

Family

ID=22629437

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106790A AR027033A1 (es) 1999-12-20 2000-12-20 Composicion estable para dosis oral de liberacion extendida

Country Status (38)

Country Link
US (2) US6979463B2 (es)
EP (2) EP1112738B1 (es)
JP (3) JP5042403B2 (es)
KR (2) KR100936572B1 (es)
CN (3) CN1211079C (es)
AR (1) AR027033A1 (es)
AT (1) ATE463240T1 (es)
AU (4) AU2277101A (es)
BR (1) BR0006403A (es)
CA (1) CA2329217C (es)
CO (1) CO5251435A1 (es)
CY (1) CY1110693T1 (es)
CZ (1) CZ302860B6 (es)
DE (1) DE60044117D1 (es)
DK (1) DK1112738T3 (es)
EC (1) ECSP003836A (es)
EG (1) EG23759A (es)
ES (1) ES2341751T3 (es)
HK (1) HK1034453A1 (es)
HU (1) HUP0004988A3 (es)
ID (1) ID28675A (es)
IL (1) IL140450A (es)
MX (1) MXPA00013037A (es)
MY (1) MY130773A (es)
NO (1) NO331645B1 (es)
NZ (1) NZ509028A (es)
PE (1) PE20010982A1 (es)
PL (1) PL211573B1 (es)
PT (1) PT1112738E (es)
RU (2) RU2303440C2 (es)
SA (2) SA06270069B1 (es)
SG (1) SG109438A1 (es)
SI (1) SI1112738T1 (es)
SK (1) SK287684B6 (es)
TR (1) TR200003787A2 (es)
TW (1) TWI225414B (es)
WO (1) WO2001045668A2 (es)
ZA (1) ZA200007715B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
CN1518448A (zh) * 2001-06-20 2004-08-04 ���鹫˾ 用于治疗鼻充血和鼻塞的抗组胺剂
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
EP1476139B1 (en) * 2002-02-21 2017-05-17 Valeant Pharmaceuticals Luxembourg S.à.r.l. Controlled release dosage forms
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
PL1507531T3 (pl) * 2003-03-12 2007-06-29 Teva Pharma Trwałe kompozycje farmaceutyczne desloratadyny
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
JP4999329B2 (ja) * 2003-12-01 2012-08-15 武田薬品工業株式会社 固形製剤の印刷前処理方法
US20060110449A1 (en) * 2004-10-25 2006-05-25 Lorber Richard R Pharmaceutical composition
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20080103746A1 (en) 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
FR2894143B1 (fr) 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
NZ573173A (en) * 2006-06-01 2012-03-30 Msd Consumer Care Inc Phenylephrine pharmaceutical formulation and compositions for colonic absorption
AR061166A1 (es) * 2006-06-01 2008-08-06 Schering Corp Composiciones farmaceuticas para la liberacion sostenida de fenilferina
PE20080313A1 (es) * 2006-06-01 2008-04-10 Schering Corp Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
US20080095843A1 (en) * 2006-07-11 2008-04-24 Nutalapati Siva R K Controlled-release formulations
MX2009013054A (es) * 2007-06-01 2010-01-15 Schering Plough Healthcare Composicion farmaceutica que comprende un sustrato y un revestimiento que contiene un ingrediente activo y alcohol polivinilico.
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
WO2010143202A1 (en) * 2009-06-09 2010-12-16 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition
TR201009396A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Desloratadin granüller
DE102016107760B4 (de) * 2016-04-26 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Essbare Funktionsschichten und Überzüge auf Hybridpolymerbasis für Pharmazie und Lebensmittel
US10463656B2 (en) 2017-01-05 2019-11-05 Iowa State University Research Foundation, Inc. Methods and compositions for prevention of feedlot bovine respiratory disease
CR20230109A (es) 2020-07-30 2023-05-11 Faes Farma Sa Sistema de liberación de fármacos descongestivos y bilastina

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100000A (en) 1870-02-22 Improved sun-bonnet for horses
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
JPS61501205A (ja) 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション ８↓−クロル↓−６，１１↓−ジヒドロ↓−１１↓−（４↓−ピペリジリデン）↓−５Ｈ↓−ベンゾ〔５，６〕シクロヘプタ〔１，２−ｂ〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4863931A (en) 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
IL98572A (en) 1990-06-22 1995-07-31 Schering Corp Bite-benzo or benzopyrido compounds Cyclohepta piperidine, piperidylidene and piperazine, preparations and methods of use.
CA2098198A1 (en) 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
MX9202350A (es) 1991-05-20 1992-11-01 Alza Corp Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol.
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
ES2042421B1 (es) 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
JP2646972B2 (ja) 1993-11-01 1997-08-27 日本電気株式会社 多ビットメモリ
DE4442999A1 (de) 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
WO1998018470A1 (en) * 1996-10-31 1998-05-07 Schering Corporation Composition, for the treatment of asthma, containing loratadine and a decongestant
PE71699A1 (es) * 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
US5900421A (en) 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6506767B1 (en) 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
AU1205799A (en) 1997-10-29 1999-05-17 J-Med Pharmaceuticals, Inc. Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
EP1380297B1 (en) 1998-07-10 2009-05-27 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclo-hepta[1,2-b]pyridine oral compositions
US6423721B1 (en) 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6051585A (en) 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
AU3800601A (en) 2000-02-03 2001-08-14 Schering Corporation Treating allergic and inflammatory conditions
PT1289945E (pt) 2000-05-19 2004-10-29 Alcon Inc Derivados dissulfureto de anilina para o tratamento de doencas alergicas
US6599913B1 (en) 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions

Also Published As

Publication number Publication date
CN101081224A (zh) 2007-12-05
HUP0004988A3 (en) 2008-04-28
ECSP003836A (es) 2002-02-25
JP5042403B2 (ja) 2012-10-03
JP2012224642A (ja) 2012-11-15
RU2303440C2 (ru) 2007-07-27
AU781924B2 (en) 2005-06-23
SA06270069B1 (ar) 2009-06-07
EP1112738B1 (en) 2010-04-07
JP2008081510A (ja) 2008-04-10
SA01210741A (ar) 2005-12-03
US7820199B2 (en) 2010-10-26
NZ509028A (en) 2002-12-20
NO20006504D0 (no) 2000-12-20
SI1112738T1 (sl) 2010-07-30
TR200003787A3 (tr) 2001-07-23
CN1211079C (zh) 2005-07-20
CZ302860B6 (cs) 2011-12-21
RU2007104095A (ru) 2008-08-10
AU2009200460B2 (en) 2012-01-19
SK287684B6 (sk) 2011-06-06
HK1034453A1 (en) 2001-10-26
CO5251435A1 (es) 2003-02-28
US20060159761A1 (en) 2006-07-20
RU2423106C2 (ru) 2011-07-10
NO331645B1 (no) 2012-02-13
EP1112738A3 (en) 2001-07-18
TWI225414B (en) 2004-12-21
AU2277101A (en) 2001-07-03
ES2341751T3 (es) 2010-06-28
EP1112738A2 (en) 2001-07-04
HU0004988D0 (es) 2001-02-28
KR101234940B1 (ko) 2013-02-19
JP2001172174A (ja) 2001-06-26
CA2329217A1 (en) 2001-06-20
PE20010982A1 (es) 2001-09-28
MXPA00013037A (es) 2003-06-19
IL140450A0 (en) 2002-02-10
CA2329217C (en) 2006-10-31
DK1112738T3 (da) 2010-06-28
ID28675A (id) 2001-06-21
EG23759A (en) 2007-08-08
KR100936572B1 (ko) 2010-01-13
SG109438A1 (en) 2005-03-30
ATE463240T1 (de) 2010-04-15
CY1110693T1 (el) 2015-06-10
PL211573B1 (pl) 2012-05-31
BR0006403A (pt) 2001-07-17
CN101081224B (zh) 2012-05-30
WO2001045668A3 (en) 2001-12-13
ZA200007715B (en) 2001-06-20
AU2009200460A1 (en) 2009-02-26
PL344715A1 (en) 2001-07-02
EP2196195A2 (en) 2010-06-16
US20030086971A1 (en) 2003-05-08
US6979463B2 (en) 2005-12-27
SK19672000A3 (sk) 2001-09-11
AU2005203771A1 (en) 2005-09-15
SA01210741B1 (ar) 2006-10-31
KR20110028326A (ko) 2011-03-17
IL140450A (en) 2011-11-30
MY130773A (en) 2007-07-31
PT1112738E (pt) 2010-06-04
KR20010062542A (ko) 2001-07-07
DE60044117D1 (de) 2010-05-20
HUP0004988A2 (hu) 2002-11-28
RU2423106C9 (ru) 2012-06-27
CN1301534A (zh) 2001-07-04
NO20006504L (no) 2001-06-21
WO2001045668A2 (en) 2001-06-28
TR200003787A2 (tr) 2001-07-23
CZ20004812A3 (cs) 2001-08-15
EP2196195A3 (en) 2012-02-29
CN1679569A (zh) 2005-10-12
AU7244300A (en) 2001-06-21

Similar Documents

Publication Publication Date Title
AR027033A1 (es) Composicion estable para dosis oral de liberacion extendida
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
BR9913948A (pt) Composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e processo para o tratamento de dor aguda
RS50924B (sr) Oralni dozni oblici propiverina ili njegovih farmaceutski prihvatljivih soli sa produženim oslobađanjem aktivne materije
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
ES2094906T3 (es) Composiciones para la administracion topica de agentes farmaceuticamente activos.
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
BR9814118A (pt) Nova composição de matéria
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
AR012376A1 (es) Formulacion de gel para la aplicacion topica
ES2164465T3 (es) Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
BR0109893A (pt) Preparação farmacêutica de lerisetron na forma de um sistema terapêutico transdêrmico, uso da preparação, uso da substância ativa lerisetron e método para administrar a substância ativa lerisetron a um paciente
AR018505A1 (es) COMPOSICIoN FARMACÉUTICA ANTIHISTAMíNICA CON UN INHIBIDOR DE LA P-GLICOPROTEíNA Y EL USO DE DICHA COMPOSICIoN PARA LA FABRICACIoN DE MEDICAMENTOS PARA AUMENTAR LA BIODISPONIBILIDAD DE DICHO ANTIHISTAMíNICO.
BR0308038A (pt) Ambroxol para o tratamento de estados doloridos na cavidade bucal e faringe
KR890009400A (ko) 다이클로닌 Hcl및 페놀을 함유하는 약제학적 조성물
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
AR017664A1 (es) Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento
BR0306778A (pt) Derivados de carboxamidina e seu uso no tratamento de doenças vasculares
BR9813775A (pt) Uso de um composto, processo para o tratamento de uma condição de cefaléia vascular, e, composição farmacêutica adequada para uso no tratamento de uma condição de cefaléia vascular.
PT927031E (pt) Composicao farmaceutica que contem nimesulide para administracao por via oral
ECSP034513A (es) Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina

Legal Events

Date Code Title Description
FC Refusal